Tauriga Sciences Inc (TAUG) |
|
Price: $0.0001
$0.00
0.000%
|
Day's High:
| $0.0001
| Week Perf:
| 0.00
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
317 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
0 |
Shares
Outstanding (Millions) |
297 |
Employees |
2 |
Revenues (TTM) (Millions $) |
0 |
Net Income (TTM) (Millions $) |
-6 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Tauriga Sciences Inc
The Company entered into an exclusive memorandum of understanding with Immunovative
Clinical Research, Inc. (“ICRI”), a Nevada corporation and wholly-owned
subsidiary of Immunovative Therapies, Ltd. (“ITL”), an Israeli corporation
pursuant to which the Company and ICRI intended to pursue a merger resulting
in Novo owning ICRI.
Green Innovations
On May 31, 2013, the Company signed an exclusive North American license agreement
with Green Innovations, Inc. (“Green Innovations”) for the commercialization
of Bamboo-Based “100% Tree Free” products including hospital grade
biodegradable disinfectant wipes. This 5-year license agreement functioned such
that profits were to be split equally between Tauriga and Green Innovations.
Bacterial Robotics
On October 29, 2013, the Company entered into a strategic alliance with Bacterial
Robotics, LLC (“Bacterial Robotics”). Bacterial Robotics owns certain
patents and/or other intellectual property related to the development of genetically
modified micro-organisms (GMOs) and GMOs tailored to perform one or more specific
functions, one such GMO being adopted to clean polluting molecules from nuclear
waste, such GMO being referred herein as the existing BactoBot Technology (the
BR Technology). Bacterial Robotics is developing a whitepaper to deliver to
the Company for acceptance. Upon acceptance by the Company, the parties will
form a strategic relationship through the formation of a joint venture in which
the Company will be the majority and controlling owner which will use the NuclearBot
Technology to further the growth of the nuclear wastewater treatment market.
The intent is for Bacterial Robotics to issue a 10-year license agreement.
Pilus Energy
On November 25, 2013, the Company entered a definitive agreement to acquire
Cincinnati, Ohio based Pilus Energy LLC (“Pilus Energy”), a developer
of alternative cleantech energy platforms using proprietary microbial solutions
that creates electricity while consuming polluting molecules from wastewater.
Upon consummation of the proposed transaction, which has been unanimously ratified
by Tauriga’s board of directors, Pilus Energy will become a wholly-owned
subsidiary of Tauriga. In addition, certain advisors of Pilus Energy will be
incorporated into the existing management team of Tauriga and report directly
to the Company’s Chief Executive Officer. A total of $100,000 was paid
by Tauriga to Bacterial Robotics in connection with the execution of this November
2013 definitive agreement for the acquisition of Pilus Energy.
Company Address: 4 Nancy Court Wappingers Falls 12590 NY
Company Phone Number: 796-9926 Stock Exchange / Ticker: TAUG
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Chromadex Corporation
CDXC, also known as ChromaDex Corporation, recently achieved a break-even point with a moderate increase in revenue. In the most recent fiscal period, their revenue rose by 0.953% to $21.20 million compared to the corresponding quarter a year prior. While this may seem positive, it is crucial to understand how CDXC performed in relation to its competitors in the legal cannabis industry. Unfortunately, CDXC underperformed in comparison to its contemporaries, who reported a business advance of 4.20% from the same quarter a year ago. The previous quarter showed some improvement for CDXC, as their revenue increased by 8.725% from $19.50 million. Additionally, they achieved earnings of $0.114 million in the most recent fiscal period, a significant improvement compared to a net shortfall of $-1.418 million in the same quarter a year ago. Despite these positive aspects, CDXC's stockpiles have increased to $14.5 million, lower than the previous year's level of $14.7 million. Additionally, their accounts receivable has declined to $5.2 million, potentially indicating slowing demand.
|
Usana Health Sciences Inc
Despite a slight decrease in revenue during the October to December 2023 period, Usana Health Sciences Inc (USNA) managed to raise its earnings per share (EPS), showing significant growth in profit. The company reported a surge of 30.06% in profit per share to $0.87, while revenue fell by -2.722% to $221.76 million year on year. Comparing these results with the prior financial reporting period, Usana Health Sciences Inc demonstrated impressive growth. EPS soared from $0.59 per share, and revenue advanced by 4.195% from $212.84 million. This shows that the company is continuing to increase its profitability, even in the face of slightly lower revenue. Furthermore, Usana Health Sciences Inc highlighted its improving profit margins, with net margin rising to 7.56% and operating margin edging up to 10.92% during the October to December 2023 period. These figures indicate the company's ability to control costs and maximize its profitability.
|
Alterola Biotech Inc
Alterola Biotech Inc, a legal cannabis company, has recently released its financial report for the October to December 2023 reporting cycle. The shareholders have not anticipated any changes in revenue during this period. However, they have expressed concerns over the company's operating loss, which amounted to $-1.108947 million. To better understand the current state of the company, it is important to compare its performance with previous quarters. In the third quarter of 2023, Alterola Biotech Inc reported an operating loss of $0.540621 million. This indicates a significant increase in losses during the October to December 2023 reporting cycle.
|
Natural Alternatives International Inc
The financial results of Natural Alternatives International Inc. for the second quarter of 2024 paint a challenging picture for the company. The significant deficit per share, declining revenue, and net loss compared to the previous year all point towards a tough period for the company. One key highlight from the results is the decline in inventories and the increase in accounts receivable. The decrease in inventories could indicate lower expected demand for the company's products, while the rise in accounts receivable could suggest an increase in sales but delayed payments. These factors can have implications for the company's future performance and growth prospects.
|
Upexi Inc
Upexi Inc, a leading player in the legal cannabis sector, has recently posted disappointing financial results for the most recent fiscal period. Despite these challenges, there are signs of potential growth and improvement on the horizon. While the company reported a loss per share of $-0.12, a decline from the previous year, it is important to note that the legal cannabis sector as a whole has seen a 32.13% increase in revenue compared to the same period a year before. This indicates that there is still strong demand and opportunity in the industry, and Upexi Inc is well positioned to capitalize on this growth.
|
Per Share |
Current |
Earnings (TTM) |
-0.02 $ |
Revenues (TTM) |
0 $
|
Cash Flow (TTM) |
- |
Cash |
0 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.02 $
|
Revenues (TTM) |
0 $ |
Cash Flow (TTM) |
- |
Cash |
0 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|